CEO Christopher Peetz was paid $10,441,224 in fiscal year 2025, ↑ up 58.2% from fiscal year 2024, the 50th percentile of its disclosed peer group (SEC filing 0001759425-26-000027 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
$10,441,224 ↑ Christopher Peetz total, FY2025 | 50th CEO pay percentile vs peers | 24:1 CEO-to-median pay ratio | 95.98% Say-on-pay support, latest vote |
Track this company's pay every filing: join the Pro seat waitlist
Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year
MIRM's next annual pay disclosure, estimated May 2, 2027.est. Filing ↗
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Peetz | $755,000 | $0 | $3,683,904 | $4,931,320 | $1,057,000 | $0 | $14,000 | $10,441,224 |
| Chief Executive Officer and Director | ||||||||
| Peter Radovich | 572,500 | 0 | 1,199,500 | 1,605,770 | 572,500 | 0 | 14,000 | 3,964,270 |
| President and Chief Operating Officer | ||||||||
| Eric Bjerkholt | 520,000 | 0 | 959,600 | 1,284,616 | 468,000 | 0 | 14,000 | 3,246,216 |
| Chief Financial Officer | ||||||||
| Joanne Quan | 520,000 | 0 | 959,600 | 1,284,616 | 468,000 | 0 | 14,000 | 3,246,216 |
| Chief Medical Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Christopher Peetz | $10,441,224 | $6,598,551 | $6,451,720 | ↑ +3,842,673 |
| Peter Radovich | 3,964,270 | 3,337,856 | 2,367,484 | ↑ +626,414 |
| Eric Bjerkholt | 3,246,216 | 2,006,255 | 4,337,928 | ↑ +1,239,961 |
| Joanne Quan | 3,246,216 | 3,589,334 | — | ↓ −343,118 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
You have just read Mirum Pharmaceuticals, Inc.'s Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper MIRM reports.
We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.
Get the Mirum Pharmaceuticals, Inc. Peer Teardown Report
$10,441,224 Christopher Peetz total, FY2025
$199
The free page is the headline. The teardown reads every company in the disclosed peer group on its own numbers.
Data as of October 14, 2026 · Source: 0001759425-26-000027 · Velarion Executive Compensation Database, deposited on Zenodo (doi:10.5281/zenodo.22283855).
Reports for MIRM
Every report below is generated from the same filings as the free brief above, at the moment of purchase. What each one adds:
Order MIRM
Pick the report, add the email the receipt and the PDF go to, and pay by card on Stripe.
How we handle your data → Privacy
The list of companies that name MIRM as a peer is temporarily unavailable — recheck shortly.
Get the Mirum Pharmaceuticals, Inc. Executive Compensation Report
$1,500
One page per director: the seat, the committees and the fee table, read for one person at a time.
| Director | Role | FY2025 total |
|---|---|---|
| Laura Brege | Independent Director | $440,468 |
| Laurent Fischer | Independent Director | $429,843 |
| Lon Cardon | Independent Director | $404,843 |
| Michael Grey | Chair of the Board | $459,843 |
| Patrick Heron | Independent Director | $409,843 |
| Saira Ramasastry | Independent Director | $421,718 |
| Timothy Walbert | Independent Director | $414,843 |
| William C. Fairey | Independent Director | $421,718 |
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Saira Ramasastry | Director | 2026-05-15 | A | 2,000 | $24 | $47,020 | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-05-15 | D | 2,000 | 109 | 218,940 | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-05-15 | D | 2,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laurent Fischer | Director | 2026-05-29 | D | 3,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lon Cardon | Director | 2026-05-29 | D | 3,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Walbert | Director | 2026-05-29 | A | 3,977 | — | — | Common | Form 4 ↗ |
| Laurent Fischer | Director | 2026-05-29 | A | 3,977 | — | — | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-05-29 | D | 3,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-05-29 | A | 3,977 | — | — | Common | Form 4 ↗ |
| Lon Cardon | Director | 2026-05-29 | A | 3,977 | — | — | Common | Form 4 ↗ |
| Timothy Walbert | Director | 2026-05-29 | D | 3,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 883 | 100 | 88,000 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 1,021 | 98 | 100,262 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 1,973 | 98 | 192,486 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 16,595 | 95 | 1,582,167 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 2,602 | 95 | 246,253 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | A | 30,000 | 3 | 88,080 | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-06-01 | D | 3,977 | 100 | 397,700 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 6,926 | 96 | 665,935 | Common, open-market sale | Form 4 ↗ |
| Peter Radovich | PRESIDENT AND COO | 2026-06-05 | D | 16,988 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Radovich | PRESIDENT AND COO | 2026-06-05 | A | 16,988 | 19 | 326,000 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-08 | D | 1,567 | 95 | 149,053 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-08 | D | 1,175 | 94 | 110,391 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-08 | D | 2,258 | 93 | 209,633 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-09 | D | 2,393 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-09 | A | 2,393 | 26 | 63,391 | Common | Form 4 ↗ |
| Michael Grey | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Dividend-equivalent accruals | 2026-06-15 | — | 15,840 | — | — | 8 insiders, 8 accrual rows | ||
| Laurent Fischer | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Heron | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Walbert | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura Brege | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lon Cardon | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William C. Fairey | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-06-17 | D | 2,594 | 102 | 264,458 | Common | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-07-01 | D | 2,721 | 120 | 326,520 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 300 | 125 | 37,482 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 528 | 124 | 65,388 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 3,124 | 122 | 380,097 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 1,710 | 125 | 213,391 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 12,134 | 122 | 1,476,101 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 1,975 | 124 | 244,387 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 4,181 | 122 | 511,504 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | A | 20,000 | 3 | 58,720 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 1,048 | 122 | 128,307 | Common, open-market sale | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-08-03 | D | 1,840 | 105 | 193,734 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | D | 6,017 | 99 | 597,187 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | A | 20,000 | 3 | 58,720 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | D | 2,300 | 100 | 230,322 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | D | 11,683 | 99 | 1,150,892 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-08-11 | D | 6,001 | 100 | 599,510 | Common, open-market sale | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-08-18 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-08-18 | D | 40,000 | 100 | 4,000,000 | Common | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-08-18 | A | 40,000 | 6 | 250,800 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-09-01 | D | 8,312 | 98 | 815,241 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-09-01 | A | 30,000 | 3 | 88,080 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-09-01 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-09-01 | D | 21,688 | 99 | 2,145,160 | Common, open-market sale | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-09-02 | D | 658 | 100 | 65,800 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-09-11 | A | 18,333 | — | — | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-09-11 | D | 18,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-09-14 | D | 9,943 | 98 | 978,093 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-10-06 | D | 6,892 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-10-06 | D | 5,305 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-10-06 | A | 6,892 | 16 | 109,376 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-10-06 | A | 5,305 | 19 | 101,803 | Common | Form 4 ↗ |
| Robert Paul Myers | Chief Medical Officer | 2026-10-09 | A | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Paul Myers | Chief Medical Officer | 2026-10-09 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Saira Ramasastry | Director | 2026-05-15 | A | 2,000 | $24 | $47,020 | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-05-15 | D | 2,000 | 109 | 218,940 | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-05-15 | D | 2,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laurent Fischer | Director | 2026-05-29 | D | 3,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lon Cardon | Director | 2026-05-29 | D | 3,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Walbert | Director | 2026-05-29 | A | 3,977 | — | — | Common | Form 4 ↗ |
| Laurent Fischer | Director | 2026-05-29 | A | 3,977 | — | — | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-05-29 | D | 3,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-05-29 | A | 3,977 | — | — | Common | Form 4 ↗ |
| Lon Cardon | Director | 2026-05-29 | A | 3,977 | — | — | Common | Form 4 ↗ |
| Timothy Walbert | Director | 2026-05-29 | D | 3,977 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 883 | 100 | 88,000 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 1,021 | 98 | 100,262 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 1,973 | 98 | 192,486 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 16,595 | 95 | 1,582,167 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 2,602 | 95 | 246,253 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | A | 30,000 | 3 | 88,080 | Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-06-01 | D | 3,977 | 100 | 397,700 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-06-01 | D | 6,926 | 96 | 665,935 | Common, open-market sale | Form 4 ↗ |
| Peter Radovich | PRESIDENT AND COO | 2026-06-05 | D | 16,988 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Peter Radovich | PRESIDENT AND COO | 2026-06-05 | A | 16,988 | 19 | 326,000 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-08 | D | 1,567 | 95 | 149,053 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-08 | D | 1,175 | 94 | 110,391 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-08 | D | 2,258 | 93 | 209,633 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-09 | D | 2,393 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-06-09 | A | 2,393 | 26 | 63,391 | Common | Form 4 ↗ |
| Michael Grey | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laurent Fischer | Director | 2026-06-15 | A | 1,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laurent Fischer | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Heron | Director | 2026-06-15 | A | 1,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Patrick Heron | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Walbert | Director | 2026-06-15 | A | 1,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Timothy Walbert | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura Brege | Director | 2026-06-15 | A | 1,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Laura Brege | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lon Cardon | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Michael Grey | Director | 2026-06-15 | A | 1,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William C. Fairey | Director | 2026-06-15 | A | 1,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| William C. Fairey | Director | 2026-06-15 | A | 3,772 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Saira Ramasastry | Director | 2026-06-15 | A | 1,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Lon Cardon | Director | 2026-06-15 | A | 1,980 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-06-17 | D | 2,594 | 102 | 264,458 | Common | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-07-01 | D | 2,721 | 120 | 326,520 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 300 | 125 | 37,482 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 528 | 124 | 65,388 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 3,124 | 122 | 380,097 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 1,710 | 125 | 213,391 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 12,134 | 122 | 1,476,101 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 1,975 | 124 | 244,387 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | D | 4,181 | 122 | 511,504 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-07-06 | A | 20,000 | 3 | 58,720 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-07-06 | D | 1,048 | 122 | 128,307 | Common, open-market sale | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-08-03 | D | 1,840 | 105 | 193,734 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | D | 6,017 | 99 | 597,187 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | A | 20,000 | 3 | 58,720 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | D | 20,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | D | 2,300 | 100 | 230,322 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-08-10 | D | 11,683 | 99 | 1,150,892 | Common, open-market sale | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-08-11 | D | 6,001 | 100 | 599,510 | Common, open-market sale | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-08-18 | D | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-08-18 | D | 40,000 | 100 | 4,000,000 | Common | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-08-18 | A | 40,000 | 6 | 250,800 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-09-01 | D | 8,312 | 98 | 815,241 | Common, open-market sale | Form 4 ↗ |
| Christopher Peetz | Director | 2026-09-01 | A | 30,000 | 3 | 88,080 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-09-01 | D | 30,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-09-01 | D | 21,688 | 99 | 2,145,160 | Common, open-market sale | Form 4 ↗ |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 2026-09-02 | D | 658 | 100 | 65,800 | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-09-11 | A | 18,333 | — | — | Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-09-11 | D | 18,333 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 2026-09-14 | D | 9,943 | 98 | 978,093 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-10-06 | D | 6,892 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-10-06 | D | 5,305 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-10-06 | A | 6,892 | 16 | 109,376 | Common | Form 4 ↗ |
| Christopher Peetz | Director | 2026-10-06 | A | 5,305 | 19 | 101,803 | Common | Form 4 ↗ |
| Robert Paul Myers | Chief Medical Officer | 2026-10-09 | A | 25,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Robert Paul Myers | Chief Medical Officer | 2026-10-09 | A | 40,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Christopher Peetz | OPTION | 2025-01-21 | — | — | 153,550 | — | $4,932,026 |
| Joanne Quan | OPTION | 2025-01-21 | — | — | 40,000 | — | 1,284,800 |
| Joanne Quan | RSU | 2025-01-21 | — | — | 10,000 | — | 479,799 |
| Peter Radovich | RSU | 2025-01-21 | — | — | 12,500 | — | 599,750 |
| Eric Bjerkholt | OPTION | 2025-01-21 | — | — | 40,000 | — | 1,284,800 |
| Eric Bjerkholt | RSU | 2025-01-21 | — | — | 10,000 | — | 479,799 |
| Christopher Peetz | RSU | 2025-01-21 | — | — | 38,390 | — | 1,841,952 |
| Peter Radovich | OPTION | 2025-01-21 | — | — | 50,000 | — | 1,605,999 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Christopher Peetz | $1,841,952 | $0 | $4,932,026 | 0.0% |
| Joanne Quan | 479,799 | 0 | 1,284,800 | 0.0% |
| Peter Radovich | 599,750 | 0 | 1,605,999 | 0.0% |
| Eric Bjerkholt | 479,799 | 0 | 1,284,800 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Peter Radovich | RSU | 25,000 | — | $1,974,750 |
| Eric Bjerkholt | RSU | 10,000 | — | 789,900 |
| Christopher Peetz | Option | 5,000 | 15.87 | — |
| Eric Bjerkholt | RSU | 5,333 | — | 421,254 |
| Christopher Peetz | RSU | 76,780 | — | 6,064,852 |
| Joanne Quan | RSU | 10,000 | — | 789,900 |
| Christopher Peetz | RSU | 75,000 | — | 5,924,250 |
| Christopher Peetz | RSU | 38,390 | — | 3,032,426 |
| Peter Radovich | RSU | 34,500 | — | 2,725,155 |
| Christopher Peetz | RSU | 25,000 | — | 1,974,750 |
| Joanne Quan | RSU | 25,000 | — | 1,974,750 |
| Eric Bjerkholt | RSU | 20,000 | — | 1,579,800 |
| Joanne Quan | RSU | 20,000 | — | 1,579,800 |
| Eric Bjerkholt | RSU | 18,333 | — | 1,448,124 |
| Eric Bjerkholt | Option | 16,667 | 26.49 | — |
| Christopher Peetz | RSU | 16,667 | — | 1,316,526 |
| Peter Radovich | RSU | 12,500 | — | 987,375 |
| Peter Radovich | RSU | 11,500 | — | 908,385 |
| Peter Radovich | RSU | 7,220 | — | 570,308 |
| Peter Radovich | RSU | 4,813 | — | 380,179 |
| Peter Radovich | Option | 15,641 | 23.48 | — |
| Christopher Peetz | Option | 54,167 | 23.48 | — |
| Christopher Peetz | Option | 78,125 | 26.49 | — |
| Christopher Peetz | Option | 153,550 | 47.98 | — |
| Peter Radovich | Option | 50,000 | 47.98 | — |
| Eric Bjerkholt | Option | 48,125 | 30.43 | — |
| Eric Bjerkholt | Option | 40,000 | 47.98 | — |
| Peter Radovich | Option | 1,250 | 15.87 | — |
| Peter Radovich | Option | 36,459 | 26.49 | — |
| Joanne Quan | Option | 39,063 | 26.72 | — |
| Joanne Quan | Option | 40,000 | 47.98 | — |
The company structures a significant portion of executive compensation to be variable, at risk, and tied directly to measurable performance to attract, retain, and reward highly qualified executives and align their interests with stockholders.
| CEO STI target (% of salary) | 70% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Alpine Rewards |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | true |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-15 | 44,534,575 | 1,866,719 | 13,247 | 95.98% | Passed |
| 2025 | 2025-05-29 | 34,671,826 | 1,455,143 | 8,894 | 95.97% | Passed |
| 2024 | 2024-06-05 | 32,709,274 | 1,125,532 | 90,453 | 96.42% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2026 | 2026-06-15 | 95.98%a |
| 2025 | 2025-05-29 | 95.97%b |
| 2024 | 2024-06-05 | 96.42%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “"For" votes from a majority of shares present in person, virtually or represented by proxy and entitled to vote on the matter. | Abstentions: No effect”.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Ratio (CEO : median employee) | 24 : 1 |
|---|---|
| CEO total compensation | $10,441,224 |
| Median employee compensation | $434,769 |
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Michael GreyIndependent · Board Chair | $110,000 | $174,988 | $174,855 | $0 | $0 | $459,843 |
| Laura BregeIndependent · Audit (Chair) · Nominating and Corporate Governance | 90,625 | 174,988 | 174,855 | 0 | 0 | 440,468 |
| Laurent FischerIndependent · Compensation (Chair) | 80,000 | 174,988 | 174,855 | 0 | 0 | 429,843 |
| Saira RamasastryIndependent · Audit · Compensation | 71,875 | 174,988 | 174,855 | 0 | 0 | 421,718 |
| William C. FaireyIndependent · Audit · Compensation | 71,875 | 174,988 | 174,855 | 0 | 0 | 421,718 |
| Timothy WalbertIndependent · Nominating and Corporate Governance (Chair) | 65,000 | 174,988 | 174,855 | 0 | 0 | 414,843 |
| Patrick HeronIndependent · Compensation | 60,000 | 174,988 | 174,855 | 0 | 0 | 409,843 |
| Lon CardonIndependent · Nominating and Corporate Governance | 55,000 | 174,988 | 174,855 | 0 | 0 | 404,843 |
| Christopher PeetzEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $300,000 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 20,000 / 20,000 / 10,000 |
| Stock ownership guideline | $150,000 |
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $604,375 |
| Equity awards (grant-date value) | $1,399,904 |
| All other compensation | $0 |
| Total cost of the board | $2,004,279 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
Of the companies Mirum Pharmaceuticals, Inc. names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.
Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Mirum Pharmaceuticals, Inc..
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Supernus Pharmaceuticals | 2025 | Jack Khattar | $1,036,000 | $6,535,029 | $7,031,545 | $846,930 | $15,501,557 |
| 2 | Corcept Therapeutics | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 3 | BridgeBio Pharma | 2025 | Neil Kumar | 1,044,000 | 10,606,275 | 1,874,992 | 0 | 14,944,585 |
| 4 | BioCryst Pharmaceuticals | 2025 | Jon Stonehouse | 728,466 | 0 | 11,132,458 | 1,052,633 | 12,951,082 |
| 5 | Crinetics Pharmaceuticals | 2025 | R. Scott Struthers | 718,500 | 3,280,540 | 7,160,564 | 462,355 | 11,628,959 |
| 6 | Vericel | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 7 | Mirum Pharmaceuticals, Inc. | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 8 | Amicus Therapeutics | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 9 | Acadia Pharmaceuticals | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 10 | Ardelyx | 2025 | Michael Raab | 797,000 | 2,953,724 | 3,413,948 | 627,638 | 7,796,171 |
| 11 | Catalyst Pharmaceuticals | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 12 | Syndax Pharmaceuticals | 2025 | Michael Metzger | 754,300 | 2,021,965 | 3,454,360 | 848,588 | 7,089,213 |
| 13 | Agios Pharmaceuticals | 2025 | Brian Goff | 846,864 | 1,291,680 | 2,627,252 | 592,804 | 5,370,389 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Mirum Pharmaceuticals, Inc. | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Acadia Pharmaceuticals | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Agios Pharmaceuticals | 100% | Option 40 · PSU 40 · RSU 20 | No | Aon |
| Amicus Therapeutics | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Ardelyx | 105% | Options 50 · RSU 50 | not disclosed | Pearl Meyer |
| BioCryst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Aon |
| BridgeBio Pharma | 135% | RSU 50 · PSU 35 · Options 15 | No | Aon Talent Solutions |
| Catalyst Pharmaceuticals | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Corcept Therapeutics | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Crinetics Pharmaceuticals | not disclosed | Options 70 · RSU 30 | not disclosed | Pearl Meyer |
| Supernus Pharmaceuticals | not disclosed | not disclosed | No | Aon |
| Syndax Pharmaceuticals | 150% | Options 34 · PSU 33 · RSU 33 | Yes — Company's three-year total shareholder return (TSR) as measured against the Nasdaq Biotechnology Index components TSRs | Aon |
| Vericel | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Christopher Peetz | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Fiscal Year 2025 Summary Compensation Table”. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 2 | Section 01, Peter Radovich | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Fiscal Year 2025 Summary Compensation Table”. As printed: 3,964,270. Filing ↗machine: r8 · c21 · span 593736–593745 |
| 3 | Section 01, Eric Bjerkholt | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Fiscal Year 2025 Summary Compensation Table”. As printed: 3,246,216. Filing ↗machine: r5 · c21 · span 586738–586747 |
| 4 | Section 01, Joanne Quan | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Fiscal Year 2025 Summary Compensation Table”. As printed: 3,246,216. Filing ↗machine: r11 · c21 · span 600446–600455 |
| 5 | Section 03, Christopher Peetz OPTION | DEF 14A | 1900-01-01 | 0001759425-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 6 | Section 03, Joanne Quan OPTION | DEF 14A | 1900-01-01 | 0001759425-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 7 | Section 03, Joanne Quan RSU | DEF 14A | 1900-01-01 | 0001759425-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 8 | Section 03, Peter Radovich RSU | DEF 14A | 1900-01-01 | 0001759425-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 9 | Section 03, Eric Bjerkholt OPTION | DEF 14A | 1900-01-01 | 0001759425-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 10 | Section 03, Eric Bjerkholt RSU | DEF 14A | 1900-01-01 | 0001759425-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 11 | Section 03, Christopher Peetz RSU | DEF 14A | 1900-01-01 | 0001759425-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 12 | Section 03, Peter Radovich OPTION | DEF 14A | 1900-01-01 | 0001759425-26-000027 | Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗ |
| 13 | Section 07, pay ratio | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “CEO Pay Ratio”. As printed: 24 : 1. Filing ↗ |
| 14 | Section 08, Michael Grey | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Director Compensation”. As printed: 459,843. Filing ↗machine: span 909244–909452 |
| 15 | Section 08, Laura Brege | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Director Compensation”. As printed: 440,468. Filing ↗machine: span 903267–903504 |
| 16 | Section 08, Laurent Fischer | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Director Compensation”. As printed: 429,843. Filing ↗machine: span 907833–908066 |
| 17 | Section 08, Saira Ramasastry | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Director Compensation”. As printed: 421,718. Filing ↗ |
| 18 | Section 08, William C. Fairey | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Director Compensation”. As printed: 421,718. Filing ↗machine: span 906289–906497 |
| 19 | Section 08, Timothy Walbert | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Director Compensation”. As printed: 414,843. Filing ↗machine: span 913971–914236 |
| 20 | Section 08, Patrick Heron | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Director Compensation”. As printed: 409,843. Filing ↗machine: span 910780–911013 |
| 21 | Section 08, Lon Cardon | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Director Compensation”. As printed: 404,843. Filing ↗machine: span 904874–905107 |
| 22 | Section 08, Christopher Peetz | DEF 14A | 2026-04-23 | 0001759425-26-000027 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 23 | Section 02, Saira Ramasastry 2026-05-15 | Form 4 | 2026-05-18 | 0001547959-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Saira Ramasastry 2026-05-15 | Form 4 | 2026-05-18 | 0001547959-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 02, Saira Ramasastry 2026-05-15 | Form 4 | 2026-05-18 | 0001547959-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 26 | Section 02, Laurent Fischer 2026-05-29 | Form 4 | 2026-06-02 | 0001379344-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 27 | Section 02, Lon Cardon 2026-05-29 | Form 4 | 2026-06-02 | 0001854337-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 28 | Section 02, Timothy Walbert 2026-05-29 | Form 4 | 2026-06-02 | 0001349376-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 29 | Section 02, Laurent Fischer 2026-05-29 | Form 4 | 2026-06-02 | 0001379344-26-000003 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 30 | Section 02, Saira Ramasastry 2026-05-29 | Form 4 | 2026-06-02 | 0001547959-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 31 | Section 02, Saira Ramasastry 2026-05-29 | Form 4 | 2026-06-02 | 0001547959-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 32 | Section 02, Lon Cardon 2026-05-29 | Form 4 | 2026-06-02 | 0001854337-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 33 | Section 02, Timothy Walbert 2026-05-29 | Form 4 | 2026-06-02 | 0001349376-26-000002 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 34 | Section 02, Christopher Peetz 2026-06-01 | Form 4 | 2026-06-02 | 0001614740-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 35 | Section 02, Christopher Peetz 2026-06-01 | Form 4 | 2026-06-02 | 0001614740-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 36 | Section 02, Christopher Peetz 2026-06-01 | Form 4 | 2026-06-02 | 0001614740-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 37 | Section 02, Christopher Peetz 2026-06-01 | Form 4 | 2026-06-02 | 0001614740-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 38 | Section 02, Christopher Peetz 2026-06-01 | Form 4 | 2026-06-02 | 0001614740-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 39 | Section 02, Christopher Peetz 2026-06-01 | Form 4 | 2026-06-02 | 0001614740-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 40 | Section 02, Christopher Peetz 2026-06-01 | Form 4 | 2026-06-02 | 0001614740-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 41 | Section 02, Saira Ramasastry 2026-06-01 | Form 4 | 2026-06-02 | 0001547959-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 42 | Section 02, Christopher Peetz 2026-06-01 | Form 4 | 2026-06-02 | 0001614740-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 43 | Section 02, Peter Radovich 2026-06-05 | Form 4 | 2026-06-08 | 0001650131-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 44 | Section 02, Peter Radovich 2026-06-05 | Form 4 | 2026-06-08 | 0001650131-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 45 | Section 02, Eric Bjerkholt 2026-06-08 | Form 4 | 2026-06-09 | 0001197350-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 46 | Section 02, Eric Bjerkholt 2026-06-08 | Form 4 | 2026-06-09 | 0001197350-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 47 | Section 02, Eric Bjerkholt 2026-06-08 | Form 4 | 2026-06-09 | 0001197350-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 48 | Section 02, Eric Bjerkholt 2026-06-09 | Form 4 | 2026-06-09 | 0001197350-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 49 | Section 02, Eric Bjerkholt 2026-06-09 | Form 4 | 2026-06-09 | 0001197350-26-000007 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 50 | Section 02, Michael Grey 2026-06-15 | Form 4 | 2026-06-17 | 0001240122-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 51 | Section 02, Laurent Fischer 2026-06-15 | Form 4 | 2026-06-17 | 0001379344-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 52 | Section 02, Laurent Fischer 2026-06-15 | Form 4 | 2026-06-17 | 0001379344-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 53 | Section 02, Patrick Heron 2026-06-15 | Form 4 | 2026-06-17 | 0001365617-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 54 | Section 02, Patrick Heron 2026-06-15 | Form 4 | 2026-06-17 | 0001365617-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 55 | Section 02, Timothy Walbert 2026-06-15 | Form 4 | 2026-06-17 | 0001349376-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 56 | Section 02, Timothy Walbert 2026-06-15 | Form 4 | 2026-06-17 | 0001349376-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 57 | Section 02, Laura Brege 2026-06-15 | Form 4 | 2026-06-17 | 0001365619-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 58 | Section 02, Laura Brege 2026-06-15 | Form 4 | 2026-06-17 | 0001365619-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 59 | Section 02, Saira Ramasastry 2026-06-15 | Form 4 | 2026-06-17 | 0001547959-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 60 | Section 02, Lon Cardon 2026-06-15 | Form 4 | 2026-06-17 | 0001854337-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 61 | Section 02, Michael Grey 2026-06-15 | Form 4 | 2026-06-17 | 0001240122-26-000005 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 62 | Section 02, William C. Fairey 2026-06-15 | Form 4 | 2026-06-17 | 0001727275-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 63 | Section 02, William C. Fairey 2026-06-15 | Form 4 | 2026-06-17 | 0001727275-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 64 | Section 02, Saira Ramasastry 2026-06-15 | Form 4 | 2026-06-17 | 0001547959-26-000016 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 65 | Section 02, Lon Cardon 2026-06-15 | Form 4 | 2026-06-17 | 0001854337-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 66 | Section 02, Jolanda Howe 2026-06-17 | Form 4 | 2026-06-18 | 0001974200-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 67 | Section 02, Jolanda Howe 2026-07-01 | Form 4 | 2026-07-02 | 0001974200-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 68 | Section 02, Eric Bjerkholt 2026-07-06 | Form 4 | 2026-07-08 | 0001197350-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 69 | Section 02, Eric Bjerkholt 2026-07-06 | Form 4 | 2026-07-08 | 0001197350-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 70 | Section 02, Eric Bjerkholt 2026-07-06 | Form 4 | 2026-07-08 | 0001197350-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 71 | Section 02, Christopher Peetz 2026-07-06 | Form 4 | 2026-07-08 | 0001614740-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 72 | Section 02, Christopher Peetz 2026-07-06 | Form 4 | 2026-07-08 | 0001614740-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 73 | Section 02, Christopher Peetz 2026-07-06 | Form 4 | 2026-07-08 | 0001614740-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 74 | Section 02, Christopher Peetz 2026-07-06 | Form 4 | 2026-07-08 | 0001614740-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 75 | Section 02, Christopher Peetz 2026-07-06 | Form 4 | 2026-07-08 | 0001614740-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 76 | Section 02, Christopher Peetz 2026-07-06 | Form 4 | 2026-07-08 | 0001614740-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 77 | Section 02, Eric Bjerkholt 2026-07-06 | Form 4 | 2026-07-08 | 0001197350-26-000008 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 78 | Section 02, Jolanda Howe 2026-08-03 | Form 4 | 2026-08-05 | 0001974200-26-000011 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 79 | Section 02, Christopher Peetz 2026-08-10 | Form 4 | 2026-08-11 | 0001614740-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 80 | Section 02, Christopher Peetz 2026-08-10 | Form 4 | 2026-08-11 | 0001614740-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 81 | Section 02, Christopher Peetz 2026-08-10 | Form 4 | 2026-08-11 | 0001614740-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 82 | Section 02, Christopher Peetz 2026-08-10 | Form 4 | 2026-08-11 | 0001614740-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 83 | Section 02, Christopher Peetz 2026-08-10 | Form 4 | 2026-08-11 | 0001614740-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 84 | Section 02, Eric Bjerkholt 2026-08-11 | Form 4 | 2026-08-12 | 0001197350-26-000009 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 85 | Section 02, Jolanda Howe 2026-08-18 | Form 4 | 2026-08-19 | 0001974200-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 86 | Section 02, Jolanda Howe 2026-08-18 | Form 4 | 2026-08-19 | 0001974200-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 87 | Section 02, Jolanda Howe 2026-08-18 | Form 4 | 2026-08-19 | 0001974200-26-000012 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 88 | Section 02, Christopher Peetz 2026-09-01 | Form 4 | 2026-09-03 | 0001614740-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 89 | Section 02, Christopher Peetz 2026-09-01 | Form 4 | 2026-09-03 | 0001614740-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 90 | Section 02, Christopher Peetz 2026-09-01 | Form 4 | 2026-09-03 | 0001614740-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 91 | Section 02, Christopher Peetz 2026-09-01 | Form 4 | 2026-09-03 | 0001614740-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 92 | Section 02, Jolanda Howe 2026-09-02 | Form 4 | 2026-09-03 | 0001974200-26-000013 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 93 | Section 02, Eric Bjerkholt 2026-09-11 | Form 4 | 2026-09-15 | 0001197350-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 94 | Section 02, Eric Bjerkholt 2026-09-11 | Form 4 | 2026-09-15 | 0001197350-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 95 | Section 02, Eric Bjerkholt 2026-09-14 | Form 4 | 2026-09-15 | 0001197350-26-000010 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 96 | Section 02, Christopher Peetz 2026-10-06 | Form 4 | 2026-10-06 | 0001614740-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 97 | Section 02, Christopher Peetz 2026-10-06 | Form 4 | 2026-10-06 | 0001614740-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 98 | Section 02, Christopher Peetz 2026-10-06 | Form 4 | 2026-10-06 | 0001614740-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 99 | Section 02, Christopher Peetz 2026-10-06 | Form 4 | 2026-10-06 | 0001614740-26-000014 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 100 | Section 02, Robert Paul Myers 2026-10-09 | Form 4 | 2026-10-14 | 0002155916-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 101 | Section 02, Robert Paul Myers 2026-10-09 | Form 4 | 2026-10-14 | 0002155916-26-000004 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 102 | Section 06, 2026 vote | Form 8-K | 2026-06-18 | 0001193125-26-275811 | Item 5.07 · say-on-pay result. As reported: 95.98% (votes for as printed: 44,534,575). Filing ↗ |
| 103 | Section 06, 2025 vote | Form 8-K | 2025-05-30 | 0001759425-25-000034 | Item 5.07 · say-on-pay result. As reported: 95.97% (votes for as printed: 34,671,826). Filing ↗ |
| 104 | Section 06, 2024 vote | Form 8-K | 2024-06-06 | 0001759425-24-000023 | Item 5.07 · say-on-pay result. As reported: 96.42% (votes for as printed: 32,709,274). Filing ↗ |
| 105 | Section 01 trend, Δ column (computed) | Computed | — | — | Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1) |
| 106 | Section 03b vehicle mix (computed) | Computed | — | — | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 107 | Section 09b board cost (computed) | Computed | — | — | Cash 604,375 + equity 1,399,904 + all other 0 = 2,004,279, summed across the director compensation table rows.machine: formula: Σ = 2,004,279 |
| 108 | Supernus Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001104659-26-053111 | CEO total compensation as printed in Supernus Pharmaceuticals's own proxy. As printed: 15,501,557. Filing ↗machine: r1 · c41 · span 430594–430604 |
| 109 | Corcept Therapeutics, Section 10b CEO total | DEF 14A | 2026-04-17 | 0001628280-26-025735 | CEO total compensation as printed in Corcept Therapeutics's own proxy. As printed: 15,303,551. Filing ↗machine: span 283504–283514 |
| 110 | BridgeBio Pharma, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001140361-26-016723 | CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531 |
| 111 | BioCryst Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-23 | 0001628280-26-026822 | CEO total compensation as printed in BioCryst Pharmaceuticals's own proxy. As printed: 12,951,082. Filing ↗machine: span 512256–512266 |
| 112 | Crinetics Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001658247-26-000030 | CEO total compensation as printed in Crinetics Pharmaceuticals's own proxy. As printed: 11,628,959. Filing ↗machine: r2 · c48 · span 589450–589460 |
| 113 | Vericel, Section 10b CEO total | DEF 14A | 2026-03-19 | 0001308179-26-000094 | CEO total compensation as printed in Vericel's own proxy. As printed: 11,156,368. Filing ↗machine: t258 · r1 · c27 · span 627744–627754 |
| 114 | Mirum Pharmaceuticals, Inc. (subject), Section 10b CEO total | DEF 14A | 2026-04-23 | 0001759425-26-000027 | CEO total compensation as printed in Mirum Pharmaceuticals, Inc.'s own proxy. As printed: 10,441,224. Filing ↗machine: r2 · c21 · span 580200–580210 |
| 115 | Amicus Therapeutics, Section 10b CEO total | DEF 14A | 2025-04-24 | 0001140361-25-015479 | CEO total compensation as printed in Amicus Therapeutics's own proxy. As printed: 8,526,943. Filing ↗machine: r2 · c25 · span 736126–736136 |
| 116 | Acadia Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-174163 | CEO total compensation as printed in Acadia Pharmaceuticals's own proxy. As printed: 8,256,518. Filing ↗ |
| 117 | Ardelyx, Section 10b CEO total | DEF 14A | 2026-04-29 | 0001140361-26-017800 | CEO total compensation as printed in Ardelyx's own proxy. As printed: 7,796,171. Filing ↗machine: r2 · c25 · span 677112–677121 |
| 118 | Catalyst Pharmaceuticals, Section 10b CEO total | DEF 14A | 2025-04-11 | 0001193125-25-079097 | CEO total compensation as printed in Catalyst Pharmaceuticals's own proxy. As printed: 7,774,160. Filing ↗ |
| 119 | Syndax Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-30 | 0001193125-26-197859 | CEO total compensation as printed in Syndax Pharmaceuticals's own proxy. As printed: 7,089,213. Filing ↗machine: span 936322–936331 |
| 120 | Agios Pharmaceuticals, Section 10b CEO total | DEF 14A | 2026-04-24 | 0001193125-26-177086 | CEO total compensation as printed in Agios Pharmaceuticals's own proxy. As printed: 5,370,389. Filing ↗machine: r2 · c31 · span 613185–613194 |
| 121 | Section 10a, Acadia Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-174163 | Acadia Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Mirum Pharmaceuticals, Inc.. Filing ↗ |
| 122 | Section 10a, Agios Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-177086 | Agios Pharmaceuticals names Mirum Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 123 | Section 10a, BioCryst Pharmaceuticals reciprocity | DEF 14A | — | 0001628280-26-026822 | BioCryst Pharmaceuticals names Mirum Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 124 | Section 10a, Supernus Pharmaceuticals reciprocity | DEF 14A | — | 0001104659-26-053111 | Supernus Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Mirum Pharmaceuticals, Inc.. Filing ↗ |
| 125 | Section 10a, BridgeBio Pharma reciprocity | DEF 14A | — | 0001140361-26-016723 | BridgeBio Pharma's most recent proxy was read; its disclosed peer group does not include Mirum Pharmaceuticals, Inc.. Filing ↗ |
| 126 | Section 10a, Syndax Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-26-197859 | Syndax Pharmaceuticals names Mirum Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 127 | Section 10a, Catalyst Pharmaceuticals reciprocity | DEF 14A | — | 0001193125-25-079097 | Catalyst Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Mirum Pharmaceuticals, Inc.. Filing ↗ |
| 128 | Section 10a, Crinetics Pharmaceuticals reciprocity | DEF 14A | — | 0001658247-26-000030 | Crinetics Pharmaceuticals's most recent proxy was read; its disclosed peer group does not include Mirum Pharmaceuticals, Inc.. Filing ↗ |
| 129 | Section 10a, Vericel reciprocity | DEF 14A | — | 0001308179-26-000094 | Vericel's most recent proxy was read; its disclosed peer group does not include Mirum Pharmaceuticals, Inc.. Filing ↗ |
| 130 | Section 10a, Amicus Therapeutics reciprocity | DEF 14A | — | 0001140361-25-015479 | Amicus Therapeutics names Mirum Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
| 131 | Section 10a, Ardelyx reciprocity | DEF 14A | — | 0001140361-26-017800 | Ardelyx names Mirum Pharmaceuticals, Inc. in its own disclosed peer group (read from its most recent proxy). Filing ↗ |
The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.
You'll confirm on The Pay Desk's sign-up page.
Get the Mirum Pharmaceuticals, Inc. Executive Compensation Report
$1,500